行情

ASND

ASND

Ascendis制药
NASDAQ

实时行情|Nasdaq Last Sale

112.51
+0.91
+0.82%
盘后: 112.60 +0.09 +0.08% 16:41 11/15 EST
开盘
111.49
昨收
111.60
最高
113.63
最低
108.42
成交量
28.37万
成交额
--
52周最高
133.96
52周最低
54.66
市值
53.49亿
市盈率(TTM)
-24.5811
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ASND 新闻

  • 收盘:美股再创新高 道指首次跨越28000点里程碑
  • 新浪美股.31分钟前
  • 周五美油期货收高1.7% 布油上涨1.6%
  • 新浪美股.45分钟前
  • 分析师:某位投资大佬可能正在“嗅探”Netflix
  • 新浪财经.1小时前
  • FAA局长:737 MAX机型获复飞批准"不受时间表指引"
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
+1.37%
制药与医学研究
+1.23%

热门股票

名称
价格
涨跌幅

ASND 简况

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
展开

Webull提供Ascendis Pharma A/S的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。